Order of HPV/Chlamydia infections and cervical high-grade precancer risk: A case-cohort study

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1756-1759

  Luostarinen, Tapio ^a   Namujju, Proscovia B ^b,c   Merikukka, Marko ^b   Dillner, Joakim ^d   Hakulinen, Timo ^a   Koskela, Pentti ^b   Paavonen, Jorma ^e   Surcel, Heljä Marja ^b   Lehtinen, Matti ^c  

^a Inst Stat Epidemiol Cancer Res   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

case cohort study; cervical precancer; Chlamydia trachomatis; human papillomavirus; order of infections

Indexed keywords

BACTERIUM ANTIBODY; VIRUS ANTIBODY;

ADULT; ARTICLE; CANCER RISK; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FINLAND; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREGNANCY; PRIORITY JOURNAL; SEROCONVERSION; UTERINE CERVIX CARCINOMA IN SITU;

CASE-COHORT STUDY; CERVICAL PRECANCER; CHLAMYDIA TRACHOMATIS; HUMAN PAPILLOMAVIRUS; ORDER OF INFECTIONS;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COHORT STUDIES; FEMALE; FINLAND; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84880266374     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28173     Document Type: Article

References (21)

1. Schiffman M, Clifford G, Buonaguro FM,. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
2. Schiffman M, Herrero R, DeSalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
3. de Sanjosé S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
4. Kapeu AS, Luostarinen T, Jellum E, et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 2009; 169: 480-8.
5. Lehtinen M, Ault KA, Lyytikäinen E, et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect 2011; 87: 372-6.
6. Arnheim Dahlström L, Andersson K, Luostarinen T, et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2541-50.
7. Luostarinen T, af Geijersstam V, Bjørge T, et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999; 80: 818-22.
8. Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007; 88: 814-22.
9. Pukkala E, Andersen A, Berglund G, et al. Nordic biological specimen banks as basis for studies of cancer causes and control-more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol 2007; 46: 286-307.
10. Kaasila M, Koskela P, Kirnbauer R, et al. Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int J Cancer 2009; 125: 2166-72.
11. Hakama M, Luostarinen T, Hakulinen T,. Survival of in situ carcinoma of cervix uteri: a 50-year follow-up in Finland. Int J Cancer 2004; 112: 1072-4.
12. Merikukka M, Kaasila M, Namujju PB, et al. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 2011; 128: 1114-9.
13. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285: 47-51.
14. Namujju PB,. Occurrence of infections with Multiple Human Papillomavirus (HPV) types among Finnish and Ugandan women. Helsinki: National Institute for Health and Welfare, 2012.
15. Stanley, M., HPV immune response to infection and vaccination. Infect Agent Cancer 2010; 5: 19.
16. Vänskä S, Auranen K, Apter D, et al. Modelling high-risk human papillomavirus infection occurrence by type following mass vaccination. PLoS One, in press.
17. Bulkmans NW, Berkhof J, Bulk S, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419-24.
18. Langholz B, Jiao J,. Computational methods for case-cohort studies. Comput Statist Data Anal 2007; 51: 3737-48.
19. Quint KD, de Koning MN, Geraets DT, et al. Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol 2009; 114: 390-4.
20. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20: 287-96.
21. Kjellberg L, Wang Z, Wiklund F, et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999; 80: 391-8.